Atara Biotherapeutics Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Atara Biotherapeutics ha aumentado sus beneficios a una tasa media anual de 0.4%, mientras que los beneficios de la industria de Biotechs han experimentado un crecimiento anual de 12.7%. Los ingresos han ido creciendo a una tasa media de 53.7% al año.

Información clave

2.5%

Tasa de crecimiento de los beneficios

21.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	48.7%
Rentabilidad financiera	n/a
Margen neto	-671.7%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

May 14

Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive

May 11

Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway

Feb 06

Here's Why Atara Biotherapeutics (NASDAQ:ATRA) Must Use Its Cash Wisely

Oct 17

Earnings Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 32% Dive

May 18

Need To Know: Analysts Are Much More Bullish On Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Feb 13

Analysts Have Just Cut Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Revenue Estimates By 16%

Nov 22

EMA panel backs approval of Atara's Ebvallo for transplant complication

Oct 14

Atara Bio to get additional $30M milestone payment under collaboration with Pierre Fabre

Sep 28

Atara: 2 Possible Regulatory Approvals For Tab-Cel, Plus CAR T Pipeline

Aug 17

Atara adds 16% ahead of Phase 2 data for multiple sclerosis candidate

Jul 12

Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Intrinsic Value Is Potentially 42% Above Its Share Price

Jul 03

Time To Worry? Analysts Just Downgraded Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Outlook

May 11

Desglose de ingresos y gastos

Cómo gana y gasta dinero Atara Biotherapeutics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:ATRA Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	35	-233	46	0
31 Dec 23	9	-276	50	0
30 Sep 23	6	-286	48	0
30 Jun 23	7	-305	56	0
31 Mar 23	57	-215	61	0
31 Dec 22	64	-228	68	0
30 Sep 22	71	-247	80	282
30 Jun 22	72	-248	81	0
31 Mar 22	24	-350	82	0
31 Dec 21	20	-340	79	0
30 Sep 21	13	-328	73	245
30 Jun 21	7	-318	68	245
31 Mar 21	4	-311	65	245
31 Dec 20	0	-307	64	0
30 Sep 20	0	-304	66	62
30 Jun 20	0	-301	71	115
31 Mar 20	0	-298	77	167
31 Dec 19	0	-291	80	216
30 Sep 19	0	-292	81	204
30 Jun 19	0	-279	79	194
31 Mar 19	0	-256	75	175
31 Dec 18	0	-231	70	167
30 Sep 18	0	-186	61	130
30 Jun 18	0	-159	55	107
31 Mar 18	0	-135	46	92
31 Dec 17	0	-119	40	81
30 Sep 17	0	-102	35	70
30 Jun 17	0	-97	31	68
31 Mar 17	0	-88	28	63
31 Dec 16	0	-79	25	57
30 Sep 16	0	-82	25	59
30 Jun 16	0	-69	22	49
31 Mar 16	0	-65	19	47
31 Dec 15	0	-57	17	42
30 Sep 15	0	-46	17	30
30 Jun 15	0	-41	14	27
31 Mar 15	0	-30	12	18
31 Dec 14	0	-28	13	15
30 Sep 14	0	-21	8	13
30 Jun 14	0	-18	7	10
31 Mar 14	0	-15	7	7

Ingresos de calidad: ATRA actualmente no es rentable.

Margen de beneficios creciente: ATRA actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: ATRA no es rentable, pero ha reducido pérdidas en los últimos 5 años a un ritmo de 0.4% por año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de ATRA en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: ATRA no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-8.9%).

Rentabilidad financiera

Alta ROE: El pasivo de ATRA supera su activo, por lo que es difícil calcular su rentabilidad financiera.

Atara Biotherapeutics Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Third quarter 2023 earnings released

Atara Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Atara Biotherapeutics, Inc. to Report Q4, 2022 Results on Feb 08, 2023

Recent updates

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA

President notifies of intention to sell stock

Consensus revenue estimates increase by 17%

New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Atara Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2024

Consensus revenue estimates increase by 117%

Price target decreased by 13% to US$4.20

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Atara Biotherapeutics, Inc. Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway

Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel®? Data in The Lancet Oncology

Consensus revenue estimates increase by 50%

Atara Biotherapeutics, Inc. has announced a Derivatives Offering in the amount of $15 million.

Atara Biotherapeutics, Inc. Announces Termination of Manher (Aj) Joshi as Executive Vice President, Chief Medical Officer, Effective as of February 2, 2024

Atara Biotherapeutics, Inc. Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

Price target increased by 17% to US$4.83

Consensus revenue estimates increase by 33%

Independent Director recently bought US$101k worth of stock

Consensus revenue estimates decrease by 27%

Price target decreased by 57% to US$6.40

Atara Biotherapeutics, Inc. Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings released

New major risk - Revenue and earnings growth

Here's Why Atara Biotherapeutics (NASDAQ:ATRA) Must Use Its Cash Wisely

Atara Biotherapeutics, Inc. Announces Plans to Submit Tab-cel® BLA in Second Quarter 2024 Following FDA Agreement on Comparability

New major risk - Share price stability

Price target decreased by 8.1% to US$14.82

Consensus revenue estimates decrease by 23%, EPS upgraded

New major risk - Revenue and earnings growth

Price target increased by 15% to US$18.48

Atara Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Financial position

Consensus revenue estimates fall by 21%

Atara Biotherapeutics, Inc. Announces Resignation of Beth Seidenberg from the Board of Directors

Insufficient new directors

Price target decreased by 13% to US$16.13

President recently sold US$61k worth of stock

Earnings Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 32% Dive

Consensus revenue estimates fall by 55%

Consensus revenue estimates fall by 61%

Price target decreased by 20% to US$14.74

Price target decreased by 13% to US$16.43

Atara Biotherapeutics, Inc. Announces Executive Changes

Consensus revenue estimates decrease by 11%, EPS upgraded

Need To Know: Analysts Are Much More Bullish On Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Pierre Fabre and Atara Biotherapeutics Announce the Transfer of the European Commission Marketing Authorization for EBVALLO(TM)

Atara Biotherapeutics, Inc. to Report Q4, 2022 Results on Feb 08, 2023

Atara Biotherapeutics Announces Changes to Its Board of Directors

Atara Biotherapeutics, Inc. Appoints Carol Gallagher as Chair of the Board of Directors

Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (Allele) of Tab-Cel(R) At the 64Th American Society of Hematology (Ash) Annual Meeting

Analysts Have Just Cut Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Revenue Estimates By 16%

Price target increased to US$23.67

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Atara Biotherapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Atara Biotherapeutics, Inc. Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022

CHMP Recommends Approval of Atara Biotherapeutics, Inc. Ebvallo (Tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

EMA panel backs approval of Atara's Ebvallo for transplant complication

Atara Bio to get additional $30M milestone payment under collaboration with Pierre Fabre

Atara: 2 Possible Regulatory Approvals For Tab-Cel, Plus CAR T Pipeline

Atara Biotherapeutics, Inc. to Terminate Kristin Yarema as Senior Vice President and Chief Commercial Officer, Effective as of November 15, 2022

Price target increased to US$25.83

Atara Biotherapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Consensus forecasts updated

Price target decreased to US$23.43